GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (XSWX:CURN) » Definitions » Common Stock

Curatis Holding AG (XSWX:CURN) Common Stock : CHF0.44 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Curatis Holding AG Common Stock?

Curatis Holding AG's quarterly common stock increased from Jun. 2023 (CHF12.79 Mil) to Dec. 2023 (CHF13.10 Mil) but then declined from Dec. 2023 (CHF13.10 Mil) to Jun. 2024 (CHF0.44 Mil).

Curatis Holding AG's annual common stock increased from Dec. 2021 (CHF1.81 Mil) to Dec. 2022 (CHF11.44 Mil) and increased from Dec. 2022 (CHF11.44 Mil) to Dec. 2023 (CHF13.10 Mil).


Curatis Holding AG Common Stock Historical Data

The historical data trend for Curatis Holding AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG Common Stock Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Common Stock
1.81 11.44 13.10

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial 10.70 11.44 12.79 13.10 0.44

Curatis Holding AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Curatis Holding AG Business Description

Traded in Other Exchanges
Address
Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.